HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellness Industry News: Rain Forest In US, Napa Hills Resveratrol Sparkle, More

Executive Summary

Peru's Ran Forest launches in US; Rebbl Collective takes on climate change, human trafficking; Napa Hills sparkles with resveratrol; more Forslean in Le-Vel's Thrive DFL; LeanLife expands testing pact with Ecovatec; and PureFormulas deploys Linc Global e-commerce tech.

You may also be interested in...



Wellness Launches: Rebbl's Elixirs, Cannovia's Founder Series, More

Healthycell Bioactive microgel supplements use Bioactive Gel delivery system; herbal beverage firm founded by anti-human trafficking non-profit launches elixirs; more CBD- and hemp-containing drinks and supplements roll out from Cannovia, other firms; and more wellness launch news.

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel